Targets › IL15
17 programs from 12 companies in 23 trials: 19 Phase 1, 4 Phase 2; Oncology, Immunology; next expected readout Nov 2026.
Cytokine that plays a major role in the development of inflammatory and protective immune responses to microbial invaders and parasites by modulating immune cells of both the innate and adaptive immune systems. Stimulates the proliferation of natural killer cells, T-cells and B-cells and promotes the secretion of several cytokines. (UniProt, P40933)
Open in Phaseline: the race on IL15, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| SWOG Cancer Research Network | Nogapendekin Alfa (N-803, ALT-803) IL-15/IL-15Rα fusion protein that activates natural killer cells | IL15, IL2RA | Phase 2 | Advanced Lung Non-Small Cell Carcinoma | Jun 2027 |
| The First Hospital of Jilin University | IL-15-armored BCMA-targeted CAR-T cells IL-15-armored CAR-T cells targeting BCMA | TNFRSF17, IL15 | Phase 2 | Relapsed/Refractory Multiple Myeloma | Jul 2028 |
| M.D. Anderson Cancer Center | NY-ESO-1 TCR/IL-15 NK NY-ESO-1 T-cell receptor (TCR)-engineered natural killer cells with IL-15 co-expression | NY-ESO-1, IL15 | Phase 1 | Synovial Sarcoma | Nov 2026 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | anti-CD19 IL10/IL15 CAR-NK anti-CD19 chimeric antigen receptor NK cells engineered to co-express IL-10 and IL-15 | CD19, IL10, IL15 | Phase 1 | B-cell Non Hodgkin Lymphoma | Dec 2026 |
| Suzhou Forlong Biotechnology | FL115 IL-15 agonist (IL-15[N72D]/IL-15Rα-sFc fusion protein) | IL15, IL15RA | Phase 1 | Locally Advanced/Metastatic Solid Tumors; Advanced Solid Tumors; Non-muscle Invasive Bladder Cancer (NMIBC) | Dec 2026 |
| Beijing Biotech | EB-DUO-CAR-NK-CEA/GCC Dual-target CAR-NK cell therapy targeting CEA and GUCY2C (or CEA and HER2, or GUCY2C and H | CEACAM5, GUCY2C, ERBB2, CEA, HER2, IL15 | Phase 1 | Colorectal Cancer; Colorectal Cancer Metastatic | Mar 2027 |
| Masonic Cancer Center, University of Minnesota | GTB-3650 Tri-specific killer engager (TriKE) targeting CD16 on NK cells, IL-15 co-stimulation, and | CD16, IL15, CD33 | Phase 1 | Myeloid Malignancy | Mar 2027 |
| Bangdong Gong | iC9/CAR19/IL15 CB-NK cell Chimeric Antigen Receptor Natural Killer Cell targeting CD19 with inducible suicide gene ( | TNFRSF9, CD19, IL15 | Phase 1 | Primary Sjogren's Syndrome | Oct 2027 |
| Innovent Biologics (Suzhou) | IBI3013 Recombinant anti-IL-15 monoclonal antibody | IL15 | Phase 1 | Healthy | Dec 2027 |
| M.D. Anderson Cancer Center | TROP2 CAR/IL-15 TGFBR2 KO NK cells CAR-T cell therapy targeting TROP2 with IL-15 transduction and TGFBR2 knockout in cord blo | TROP2, IL15, TGFBR2 | Phase 1 | Head and Neck Cancer | Dec 2027 |
| M.D. Anderson Cancer Center | TGFBR2 KO CAR27/IL-15 NK cells TGFBR2 knock-out cord blood-derived NK cells transduced with IL-15 and engineered with CAR | TGFBR2, IL15 | Phase 1 | Myeloid Malignancies | May 2028 |
| M.D. Anderson Cancer Center | TGFBR2 KO CAR27/IL-15 NK cells TROP2-targeted CAR-NK cells with IL-15 co-expression and TGFBR2 knockout | TROP2, TGFBR2, IL15 | Phase 1 | Gastric Cancer, Metastatic; Lymphoid | Jul 2028 |
| M.D. Anderson Cancer Center | Allogeneic Anti-NY-ESO-1-TCR-IL-15-transduced Cord Blood-derived Natural Killer Cord blood-derived NK cells transduced with NY-ESO-1 T-cell receptor and IL-15 | NY-ESO-1, IL15 | Phase 1 | Relapsed/Refractory Myeloma | Aug 2028 |
| University of California, Irvine | COH06 Genetically engineered NK cells expressing PD-L1 and expressing/secreting IL-15 | PDCD1LG2, IL15 | Phase 1 | Advanced Lung Non-Small Cell Carcinoma | Nov 2028 |
| UNC Lineberger Comprehensive Cancer Center | iC9.GD2.CAR.IL-15 T-cells CAR-T cells targeting GD2 with IL-15 co-expression and inducible caspase-9 safety switch | GD2, IL15 | Phase 1 | Neuroblastoma | May 2030 |
| M.D. Anderson Cancer Center | CAR.5/IL15-transduced CB-NK cells CD5-targeted CAR NK cells engineered with IL-15 | CD5, IL15 | Phase 1 | Hematological Malignancy | Dec 2030 |
| Instituto de Investigación Hospital Universitario La Paz | NK cells stimulated ex vivo with IL-15 Natural Killer cells stimulated ex vivo with IL-15 to enhance cytotoxic function | IL15 | Phase 1 | High-risk Leukemias | – |
Relapsed/Refractory Multiple Myeloma (3) Advanced Lung Non-Small Cell Carcinoma (2) B-cell Non Hodgkin Lymphoma (1) Hematological Malignancy (1) Gastric Cancer, Metastatic (1) Lymphoid (1) Myeloid Malignancies (1) Colorectal Cancer (1) Colorectal Cancer Metastatic (1) Relapsed/Refractory Myeloma (1) Primary Sjogren's Syndrome (1) Neuroblastoma (1)
mixed (8), small molecule (5), other (3), protein or peptide (1)
M.D. Anderson Cancer Center (6) Second Affiliated Hospital, Zhejiang University, School of Medicine (1) The First Hospital of Jilin University (1) Beijing Biotech (1) Bangdong Gong (1) University of California, Irvine (1) UNC Lineberger Comprehensive Cancer Center (1) Masonic Cancer Center, University of Minnesota (1) Suzhou Forlong Biotechnology (1) SWOG Cancer Research Network (1) Instituto de Investigación Hospital Universitario La Paz (1) Innovent Biologics (Suzhou) (1)
TGFBR2 (3) CD19 (2) TROP2 (2) NY-ESO-1 (2) IL10 (1) CD5 (1) TNFRSF17 (1) CEACAM5 (1) GUCY2C (1) ERBB2 (1) CEA (1) HER2 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.